• OPEN AN ACCOUNT
Indian Indices
Sensex
78,954.76 373.76
( 0.48%)
Global Indices
Nasdaq
54,370.92 264.04
(0.49%)
Dow Jones
7,742.03 -15.49
(-0.20%)
Hang Seng
65,663.80 -636.64
(-0.96%)
Nikkei 225
10,873.25 -15.05
(-0.14%)
Forex
USD-INR
95.23 -0.06
(-0.07%)
EUR-INR
109.68 -0.11
(-0.10%)
GBP-INR
127.98 -0.19
(-0.15%)
JPY-INR
0.60 0.00
(-0.60%)

EQUITY - MARKET SCREENER

Advanced Enzyme Technologies Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
540025
INE837H01020
63.3529756
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ADVENZYMES
27.57
3722.65
EPS(TTM)
Face Value()
Div & Yield %
12.06
2
1.61
 

Lupin receives EMA approval for Pediatric Indication of NaMuscla
Jul 01,2026
Lupin today announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, supported by the Pediatric Investigation Plan (PIP). The approval includes two new dosage strengths, 62 mg and 83 mg capsules, in addition to the existing 167 mg, and the revised indications that cover symptomatic treatment of myotonia in children (6¨C11 years, weighing at least 20 kg), adolescents (12¨C17 years), and adults (¡Ý18 years) with non-dystrophic myotonic disorder.